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This  work  reports,  for the  ﬁrst  time,  the  puriﬁcation,  characterization  and  antibacterial  activity  of  an  elas-
tase  inhibitor  from  Lasiodora  sp.  hemocytes  (EILaH).  The  hemocyte  extract  inhibited  chymotrypsin  (22%),
trypsin  (44%),  tissue  plasminogen  activator  (52%),  urokinase  (58%)  and  human  neutrophil  elastase  (99%).
EILaH  was  puriﬁed  by Trypsin-Sepharose  column  and  RP-HPLC.  SDS-PAGE  of EILaH  revealed  a molecu-
lar  mass  of  8 kDa  and  MALDI-TOF  mass  spectrometry  revealed  a single  molecular  mass  of 8274  Da.  Theeywords:
erine protease inhibitor
ntibacterial  activity
emocytes
asiodora  sp.
pider
amino  terminal  sequence  determined  was  LPC(PF)PYQQELTC.  The  dissociation  constant  (Ki)  for  human
neutrophil  elastase  was  0.32  nM.  Hemocyte  extract  exerted  antibacterial  effect  on Bacillus  subtilis  and
Enterococcus  faecalis,  while  EILaH  was  only  active  against  E.  faecalis.  Currently,  Lasiodora  sp.  is undergo-
ing  a  systematic  review  and  this  study  contributes  to molecular  characterization  of  the  genus.  In  addition,
the  results  suggest  that  serine  protease  inhibitors  expressed  in Lasiodora  sp.  hemocytes  may  be  involved
in  the  defense  against  bacterial  infection.. Introduction
Arachnids comprise the largest and, from a human standpoint,
he most important and numerous class of chelicerates, among
hich the most common and best known are spiders, scorpions,
ites and ticks. The Brazilian spider Lasiodora (Mygalomorphae,
heraphosidae), whose trivial names are “caranguejeira” or taran-
ula, is distributed in northeastern Brazil, in the rainforest [1].
piders are the most diverse and successful terrestrial invertebrates
fter insects, which are their primary prey [2]. This success is due
o innate immunity, carried out mostly by hemocytes, and includes
ellular as well as humoral responses [3].
In arthropods, phagocytosis, complement, antimicrobial pep-
ides, coagulation and melanization are instances of cellular
efenses, while humoral defense usually involves components
eleased from hemocytes [4–8]. It has been suggested that a serine
rotease inhibitor released from blood cells protects the arthropod
rom microbial infection by inhibiting fungal or bacterial pro-
einases as well as by regulating endogenous proteinases involved
∗ Corresponding author. Tel.: +55 8121268540; fax: +55 8121268576.
E-mail address: ppaivaufpe@yahoo.com.br (P.M.G. Paiva).
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in host-defense mechanisms [9–11]. Limulus hemocytes are able
to detect the lipopolysaccharide present in Gram-negative bacte-
ria cell wall, starting the exocytose of hemocyte large granules,
which contain protease inhibitors and pseudo-serine protease with
antimicrobial activities [9].
Protease inhibitors are essential for all organisms, and play a
major role in controlling protein damage of self and non-self pro-
teases [12]. They inhibit serine, cysteine and aspartic acid proteases,
as well as metalloproteinases. Additionally, the best character-
ized families of protease inhibitors are Kazal, Kunitz and Pacifastin
[13–15]. Serine protease inhibitors play important roles as modu-
lators of several biological processes such as apoptosis, digestion,
prophenol oxidase activation, blood coagulation, cellular remod-
eling, metamorphosis, complement system and defense against
invading organisms [16–21]. Elastase inhibitors have been isolated
from numerous invertebrates, including the locust Schistocerca gre-
garia [22], the shrimp Penaeus monodon [13,23,24], the kissing bug
Triatoma infestans [12], the tick Boophilus microplus [6,25,26] and
Rhipicephalus (B.) microplus [27].
Open access under the Elsevier OA license.In addition to their physiological role, protease inhibitors
have important medical applications. It has been suggested that
inhibitors of the neutrophil elastase could be useful in the treat-
ment of pulmonary diseases [28]. In addition, recombinant versions
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f naturally occurring inhibitors and synthetic small inhibitors
re potential therapeutic agents in the treatment of respira-
ory diseases [28]. Since the description of antibacterial effect
f serine proteinase inhibitors, a growing interest in the use of
hese inhibitors as potential antibiotics has emerged [29]. The
ecretory leukocyte protease inhibitor (SLPI), which decreases
lastase activity, has multiple medical applications, including anti-
nﬂammatory, anti-bacterial and anti-viral properties [30].
The  studies on the spider immune system have focused only on
ntimicrobial peptides. Hemocytes defensins and ctenidins active
gainst bacteria and fungi are released into the hemolymph upon
nfection [3,31]. However, to the best of our knowledge, no pro-
ease inhibitor has been puriﬁed from Lasiodora sp. hemocytes. In
his scenario, the aims of the present study were to isolate and char-
cterize an elastase inhibitor from Lasiodora sp. hemocytes (EILaH)
nd to evaluate its antibacterial activity.
. Materials and methods
.1.  Spiders and sample collection
The  animals used in the experiments were adult females in the intermolt stage,
ince  the more static behaviour in captivity and larger size characteristic of this
evelopment stage facilitate manipulation and puncture, when compared to adult
ales. Hemolymph was  collected from 16 spiders (approximately 1 ml  per animal)
y cardiac puncture with an apyrogenic syringe in 3% NaCl supplemented with 2 mM
ropanolol, to avoid coagulation. The hemocytes were obtained from plasma by
entrifugation at 800 g for 10 min  at 28 ◦C.
.2. Hemocyte extract
Hemocytes were dried by lyophilisation and macerated in 100 l of 0.15 M NaCl.
hen,  900 l of 0.15 M NaCl was added. The macerated hemocyte mass was  cen-
rifuged  at 800 g for 10 min  at 28 ◦C and the supernatant was collected and stored
t −20 ◦C. This procedure was repeated several times and all the supernatants were
ooled (26 ml) to obtain the hemocyte extract used for inhibitor puriﬁcation.
.3. Protein determination
Protein concentration in hemocyte extract, as well as in the samples obtained
fter  each step of inhibitor puriﬁcation, was determined using the Coomassie Blue
ye binding method [32]. Bovine serum albumin was used as standard protein.
.4. Protease inhibition assay
The  protease inhibition assay was carried out by pre-incubating the hemocyte
xtract  (100 l; 1.8 mg/ml  of protein) with the enzymes chymotrypsin, trypsin and
hrombin obtained from Sigma (St. Louis, MO)  as well as human neutrophil elas-
ase (HNE), plasmin, factor Xa, tissue plasminogen activator (tPA), subtilisin A and
rokinase obtained from Calbiochem (San Diego, CA). Human plasma kallikrein
as  prepared as previously described by Sampaio et al. [33]. After 10 min  at 37 ◦C,
peciﬁc substrates (Chromogenix, Sweden) were added to a ﬁnal concentration
f  0.2 mM:  Suc (Ala)2-Pro-Phe-pNa (4 mM chymotrypsin), Suc-Ala-Ala-Pro-Val-
NA  (4 mM HNE), HD-Val-Leu-Lys-pNA (4 mM plasmin), tosyl-Gly-Pro-Arg-pNA
4  mM trypsin), Glu-Gly-Arg-pNa (10 mM urokinase), Bz-Ile-(OR)-Gly-Arg-pNA
4  mM factor Xa), HD-Pro-Phe-Arg-pNA (3.64 mM plasma kallikrein-HuPK), Boc-
ly-Gly-Leu-pNa (4 mM subtilisin), HD-Phe-Pip-Arg-pNA (4 mM thrombin) and
D-Ile-Pro-Arg-pNA (4 mM tPA). The enzyme activities in the presence of hemocyte
xtract  (residual activities) were determined by measuring absorbance at 405 nm
fter incubation for 15 min  at 37 ◦C, using a spectrophotometer (ThermoLabsystems,
inland;  model iEMS). Control reactions were performed under the same condi-
ions,  without the inhibitor. One unit of protease activity was  deﬁned as the amount
f enzyme that hydrolyzes 1 mol  of substrate per minute. Inhibition percentages
ere  calculated as follows: % inhibition = 100 − [100 × (residual activity/activity in
ontrol)].
.5. Isolation of elastase inhibitor by afﬁnity chromatography on
rypsin-Sepharose and reversed-phase chromatography
The hemocyte extract exerting inhibitory activity against proteases was loaded
26  ml;  46.86 mg  of protein) onto a Trypsin-Sepharose column (1 ml)  equilibrated
ith  50 mM Tris-HCl pH 8.0 at a ﬂow rate of 0.16 ml/min, of which 1 ml  fractions
ere  collected. Proteins were eluted with 0.5 M KCl–HCl pH 2.0 at the same ﬂow
nd  the pH was  neutralized by adding 50 l of 1 M Tris-HCl pH 8.0. Protein was mea-
ured by absorbance at 280 nm.  The pool of eluted fractions (0.18 mg/ml  of protein)
as evaluated by protease inhibition assay described in Section 2.4 using the same
nzymes and substrates, and a sample volume of 100 l.stry 46 (2011) 2317–2321
The  material eluted from Trypsin-Sepharose chromatography was applied
(3.06  mg of protein) in a Sephasil Peptide C18 column connected to an ÄKTA System
(GE  Healthcare) pre-equilibrated with 0.1% triﬂuoroacetic acid (TFA) at the ﬂow rate
of 0.5 ml/min, and 1 ml  fractions were collected. Peptides were eluted with a 0–90%
acetonitrile linear gradient in 0.1% TFA. The single peptide peak eluted from the col-
umn was  evaluated for inhibitory activity on trypsin and elastase, using the same
enzyme and substrate concentrations described in Section 2.4, and a sample volume
of 5 l (7 g/ml of protein). Puriﬁed elastase inhibitor was  named EILaH (Elastase
Inhibitor  from Lasiodora sp. Hemocytes).
2.6. SDS-PAGE analysis
Samples were analyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) according to Laemmli [34]. The concentration of acrylamide
was  12% in the separating gel and 5% in the stacking gel. Gels were stained with
Silver (BioAgency, Brazil). The molecular weight standards (Sigma, USA) were:
-galactosidase  (116 kDa), phosphorylase b (97 kDa), albumin (66 kDa), glutamic
dehydrogenase  (55 kDa), ovalbumin (45 kDa), carbonic anhydrase (29 kDa), trypsin
inhibitor (20 kDa), -lactalbumin (14.2 kDa) and aprotinin (6.5 kDa).
2.7. Determination of dissociation constant (Ki)
The dissociation constant of EILaH with HNE (Calbiochem®) was  determined
according  to Bieth [35]. Brieﬂy, the 4 mM serine protease was incubated at
37 ◦C with increasing concentrations of EILaH in 0.1 M Tris-HCl pH 8.0 contain-
ing  0.15 M NaCl and 0.1% Triton X-100, and enzyme activity was  measured after
addition  of chromogenic substrate Suc-Ala-Ala-Pro-Val-pNA (ﬁnal concentration
of  0.2 mM). Enzymatic activity was measured by absorbance at 405 nm using
a Synergy HT microplate reader (BioTek). The residual activity corresponded to
HNE activity in presence of EILaH. Inhibition percentages were calculated as fol-
lows: % inhibition = 100 − [100 × (residual HNE activity/HNE activity in control)].
The  Ki value was  calculated by ﬁtting the steady-state velocities to the equa-
tion  (Vi/Vo = 1 − {Et + It + Ki − [(Et + It + Ki)2 − 4EtIt]1/2}/2Et) for the tight-binding
inhibitor using a non-linear regression analysis [36].
2.8.  Molecular identiﬁcation
EILaH molecular mass determination was  carried out on a TOF Spec E mass spec-
trometer (Micromass, Manchester, UK) operating in linear mode using the matrix
assisted laser desorption ionization time-of-ﬂight (MALDI-TOF) method, using -
cyano-4-hydroxycinnamic acid as the matrix.
The N-terminal amino acid sequence of EILaH was determined by Edman degra-
dation  [37] using a PPSQ-23 Model Protein Sequencer (Shimadzu, Japan). Acquired
data  were searched against all available sequences in the NCBI non-redundant
database  using blastp (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
2.9. Antibacterial activity
Gram-positive (Bacillus subtilis ATCC-6633, Staphylococcus aureus ATCC-6538
and  Enterococcus faecalis ATCC-6057) and Gram-negative (Escherichia coli ATCC-
25922 and Klebsiella pneumoniae ATCC-29665) bacterial strains were provided by
the Departamento de Antibióticos, Universidade Federal de Pernambuco, Brazil. Sta-
tionary cultures were maintained in nutrient agar (NA) and stored at 4 ◦C. Bacteria
were  cultured in nutrient broth (NB) and incubated under constant shaking at 37 ◦C
overnight. The cultures were adjusted turbidimetrically at a wavelength of 490 nm
to 1.5 × 108 colony forming units (CFU)/ml (0.5 in McFarland scale).
The  samples (hemocyte extract and EILaH) were concentrated by lyophilisation
and  ressuspended in 0.15 M NaCl. Aliquots (100 l) of hemocyte extract (6.8 mg/ml
of protein) or EILaH (0.455 mg/ml of protein) were diluted 1:2 in NB (100 l) and
submitted  to a series of ten double dilutions, to a ﬁnal ratio of 1:2048. Next, a 180 l
aliquot of each dilution was dispensed into a microtiter plate well. After, all the
wells were inoculated with 20 l of the bacterial culture and incubated at 37 ◦C for
24 h. The assay was performed in triplicate. Control assay contained NB medium and
microorganism. After incubation, optical density was measured at 490 nm (OD490)
using a microplate reader. Minimal inhibitory concentration (MIC) was determined
and  corresponded to the lowest protein concentration at which the optical density
decreased by more than 50% in comparison to the control OD490 [38].
Minimal bactericide concentration (MBC) was determined starting from the
results  of MIC  assay. Inoculations (10 l) from the wells in which the sample inhib-
ited  bacterial growth were transferred to NA plates. The number of CFU grown in
plates was  determined after incubation at 37 ◦C for 24 h. The MBC  corresponded to
the minimum concentration of protein in which no bacterial growth was observed.
3. ResultsLasiodora sp. hemocyte extract (1.8 mg/ml  of protein) inhibited
chymotrypsin (22%), trypsin (44%), TPA (52%), urokinase (58%) and
HNE (99%); inhibition of factor Xa, thrombin, plasmin, HuPK and
subtilisin was not detected. Hemocyte extract inhibited E. faecalis
T. Soares et al. / Process Biochemistry 46 (2011) 2317–2321 2319
Table  1
Summary of EILaH puriﬁcation.
Sample Volume (ml) Total protein (mg) Total activity (mU)a Speciﬁc activity (mU/mg)b Yield (%)c Puriﬁcation (fold)d
Hemocyte extract 26 46.86 894.4 19.08 100 1
Trypsin-Sepharose chromatography 17 3.06 40.8 13.33 4.56 0.69
EILaH 1.25  0.0087 0.6 68.96 0.07 3.61
a Inhibitory activity on human neutrophil elastase (HNE). One unit of elastase inhibitor unit corresponds to the number of units of HNE activity inhibited by the sample.
ein content (mg).
ter each puriﬁcation stage.
 and speciﬁc activity of crude extract.
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Fig. 1. Puriﬁcation of EILaH from hemocytes of Lasiodora sp. (A) Afﬁnity chromatog-
raphy  on Trypsin-Sepharose of hemocyte extract. Non-adsorbed and eluted fractions
were evaluated for protein by absorbance at 280 nm (–) and for trypsin (· · · ·) and
neutrophil  elastase (- - - -) inhibitory activities. The arrow indicates the start of the
elution step. (B) Reversed phase chromatography on Sephasil Peptide C18 column
of EILaH puriﬁed from the eluate of chromatography on Trypsin-Sepharose. Pro-
tein elution was done by linear acetonitrile gradient (0–90%) and was monitoredb Speciﬁc activity was calculated by the ratio of total activity (mU) and total prot
c Yield corresponded to the amount of total activity in crude extract recovered af
d Puriﬁcation was  measured as the ratio between the speciﬁc activity in the stage
nd B. subtilis growth, and MIC  values determined were 3400 g/ml
f protein. The extract did not inhibit the growth of S. aureus, E. coli
nd K. pneumoniae. Similarly, it had no bactericidal effect on E.
aecalis and B. subtilis.
Elastase  inhibitor (EILaH) was successfully isolated from hemo-
yte extract by two chromatographic steps (Table 1). The extract
as applied on Trypsin-Sepharose column and the adsorbed frac-
ions eluted with 0.5 M KCl–HCl pH 2.0 showed inhibitory activity
nly on trypsin and HNE (Fig. 1A). The fractions with inhibitory
ctivity obtained from the afﬁnity column were pooled and evalu-
ted by SDS-PAGE, producing multiple polypeptide bands (Fig. 1C,
ane 2). The pool was further puriﬁed on Sephasil C18 column
Fig. 1B). The eluted peptide (44 g) showed inhibitory activity only
n HNE, corresponding to EILaH. Puriﬁed EILaH was shown to be
omogeneous by SDS-PAGE with a molecular mass of 8 kDa (Fig. 1C,
ane 3).
EILaH was a strong neutrophil elastase inhibitor (Fig. 2A). When
he equation for tight-binding inhibitors was used, the inhibition
ata for EILaH ﬁtted well to the mechanism of these inhibitors, and a
issociation constant (Ki) of 0.32 ± 0.021 nM was  calculated. EILaH
olecular mass was conﬁrmed by MALDI-TOF mass spectrome-
ry, which revealed a single molecular mass of 8274 Da (Fig. 2B).
he amino terminal sequence determined was LPC(PF)PYQQELTC (a
ingle-letter code where letters in parenthesis indicate that either
roline or phenylalanine may  take this position). Alignment with
nown sequences in the NCBI non-redundant database did not
ndicate any similarity with other protease inhibitors. EILaH was
ctive against E. faecalis (MIC of 227.5 g/ml) and did not inhibit
he growth of B. subtilis, S. aureus, E. coli and K. pneumoniae.
.  Discussion
Proteases comprise a broad range of hydrolytic enzymes which
atalyze the cleavage of targeted protein substrates. Hydrolysis of
eptide bonds occurs by means of nucleophilic attack, which how-
ver is governed by different catalytic mechanisms.
Protease inhibitors are important molecules for invertebrate
nimals to control extracellular serine protease cascades that medi-
te rapid defense responses upon wounding or pathogen infection.
everal inhibitors belonging to the families Kunitz and Serpin have
een isolated, especially from hemolymph of arthropods. In this
tudy, it is demonstrated that hemocytes from the tarantula spider
asiodora sp. contain a powerful neutrophil elastase inhibitor, here
amed EILaH.
The  Lasiodora sp. hemocyte extract was a preparation rich in
nhibitors of different serine proteases, and showed antibacterial
ctivity. Yet, several have been the preparations rich in protease
nhibitors that likewise showed antibacterial activity [6,39]. It has
een reported that antibacterial activity of protease inhibitors
nvolves binding to and disruption of the bacteria membrane,
nd that the serine proteinase inhibitor released from blood cells
nhibits bacterial, as well as endogeneous proteinases that regulate
mmune responses [10,40].
Hemocyte extract was chromatographed on Trypsin-Sepharose
atrix and the material eluted from the column inhibited only
by  absorbance at 280 nm. Only the fraction represented by an arrow exhibited
inhibitory  activity, only against human neutrophil elastase, corresponding to EILaH.
(C) SDS-PAGE of molecular mass markers (1), the sample (40 g) eluted from
Trypsin-Sepharose  column (2) and EILaH (80 g) (3).
2320 T. Soares et al. / Process Biochemi
Fig. 2. Characterization of EILaH. (A) Inhibition curve used to calculate the dissocia-
tion  constant (Ki = 0.32 nM)  of EILaH for human neutrophil elastase. The percentage
of  residual HNE activity was determined by the ratio between residual activity in
presence of EILaH and the HNE activity in absence of the inhibitor. (B) MALDI-TOF-
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participation in the innate immunity of Lasiodora. However, fur-S  of EILaH.
rypsin and HNE, indicating that this chromatography step was
mportant to exclude inhibitors of other proteases present in the
emocyte extract. SDS-PAGE revealed the presence of multiple
olypeptide bands, probably different trypsin inhibitors. The EILaH
eptide, although present in the eluted sample from Trypsin-
epharose colunm, was not detected by SDS-PAGE when 40 g of
rotein were applied on gel, probably due to its lower concentra-
ion, when compared to other proteins in the sample. On another
and, low protein resolution and separation were achieved by elec-
rophoresis when 80 g of protein were used (data not shown).
The ﬁnal puriﬁcation of EILaH was obtained by a reversed phase
hromatography and the homogeneity of preparation was demon-
trated by detection of a single peptide on SDS-PAGE and a single
olecular mass by MALDI-TOF, revealing the absence of contam-
nant molecules. These results indicate that this chromatographic
tep removed trypsin inhibitors other than EILaH that were present
n the material from afﬁnity column. The removal of a great num-
er of other inhibitors may  be the reason for the low activity yield
fter this puriﬁcation stage, as shown in Table 1. SDS-PAGE sep-
ration efﬁciency of proteins with a molecular mass of less than
0 kDa is usually low but this method was able to detect EILaH pep-
ide (8 kDa) as well as the serine protease inhibitor isolated from B.
icroplus (8 kDa) [41].
EILaH was active against HNE after RP-HPLC, but not against
rypsin. Probably, the elution conditions promoted structural
hanges in EILaH, impairing its ability to bind trypsin, but did not
ffect the ability to inhibit HNE. Another possibility is that EILaH
fﬁnity for HNE is much higher than for trypsin, pointing to the
eed for high amounts of puriﬁed inhibitor required to inhibit
rypsin. The EILaH structure required to inhibit HNE was  resis-
ant to denaturation by acetonitrile after RP-HPLC, similarly to the
NE/chymotrypsin inhibitor isolated from the ovary gland of Schis-
ocerca gregaria [22].stry 46 (2011) 2317–2321
Arthropods have a wide range of trapping-(which form irre-
versible complexes with target proteases) and tight-binding (which
bind strong but reversible to proteases) inhibitors [42]. Since
most serine proteases puriﬁed from invertebrates are tight-binding
inhibitors, we chose this inhibition mechanism to evaluate the
data obtained with EILaH. The effect of EILaH on HNE ﬁtted well
on this mechanism, and the equation used allowed the calcula-
tion of a Ki value of 0.32 nM,  clearly revealing the high afﬁnity of
puriﬁed EILaH for elastase. The elastase inhibitors isolated from
B. microplus and S. gregaria also showed Ki(s) in the nM range
[22,41]. EILaH molecular mass (8274 Da) is similar to those of
the inhibitors isolated from B. microplus (8000 Da)  and S. gregaria
(9229 Da).
Amino acid sequencing showed only one N-terminal sequence
(LPC(PF)PYQQELTC), conﬁrming that EILaH was  not contaminated
with another polypeptide chain. Partial amino acid sequences
have been reported for proteins isolated from small animals.
The N-terminal sequence AVFAIQDQPC was determined for the
polypeptide from Phoneutria nigriventer spider venom responsi-
ble for the increased vascular permeability in rabbit skin, and the
N-terminal sequence DHEVTS was reported for trypsin inhibitor
puriﬁed from the skin secretions of frog Kaloula pulchra hainana
[43,44].
EILaH amino acid sequence did not show any similarity with
known members of the family of protease inhibitors. Similarly, nei-
ther the N-terminal sequence of the elastase inhibitor isolated from
Bufo andrewsi skin secretions nor the whole sequence of S. gregaria
inhibitor showed any similarity with other known serine protease
inhibitors [22,45].
Antibacterial assays revealed that B. subtilis was sensible to
hemocyte extract, but not to EILaH, and that both Lasiodora prepa-
rations inibited the growth of E. faecalis. The MIC  value determined
for EILaH was  15 times lower than that of hemocyte extract,
indicating that puriﬁcation of EILaH promoted increase in antibac-
terial activity. These data suggest that Lasiodora hemocytes contain
other antibacterial agents besides EILaH active against B. subtilis,
and that the weak bacteriostatic effect of hemocyte extract on
E. faecalis may  be associated to the low concentration of EILaH
in this crude preparation. Coexistent anti-proteolytic and anti-
microbial functions have also been demonstrated for elastase
inhibitor isolated from human lung [46]. Nevertheless, the high
MIC value, in a clinical perspective, indicates that EILaH is not
suitable for practical application as a good antibacterial agent on
E. faecalis.
Lasiodora has an open circulatory system and the presence of
EILaH probably is important for the protection of animals against
infection by E. faecalis, a pathogen of arthropods [47]. Similarly, it
has been suggested that the antibacterial activity of serine protease
inhibitor of epithelial and gland cells from Hydra magnipapillata is
involved in Hydra’s innate host defense [48].
Most hemocytes of other arthropods closely related to spiders
contain granulocytes with internal granules that release their con-
tents when the presence of microbial invaders is detected. The
Lasiodora hemocytes may  contain elastase as a protease involved
in anti-inﬂammatory processes, and EILaH may  have a role in reg-
ulating the elastase molecules.
The current literature includes studies about the toxins in
Lasiodora sp. venom [49–51], but no investigation on serine pro-
tease inhibitors in hemocytes has been reported. EILaH is the
ﬁrst elastase inhibitor with bacteriostatic activity isolated from
hemolymph cells of Lasiodora sp. The deleterious effect of EILaH
against arthropod pathogen (E. faecalis) is an indicative of itsther studies are necessary to elucidate the physiological role of
EILaH in this arthropod species as well as other potential medical
applications.
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